Leslie A Fecher

Leslie A Fecher

UNVERIFIED PROFILE

Are you Leslie A Fecher?   Register this Author

Register author
Leslie A Fecher

Leslie A Fecher

Publications by authors named "Leslie A Fecher"

Are you Leslie A Fecher?   Register this Author

25Publications

711Reads

26Profile Views

Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.

Semin Liver Dis 2018 Nov 24;38(4):366-378. Epub 2018 Oct 24.

Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0038-1667358
Publisher Site
http://dx.doi.org/10.1055/s-0038-1667358DOI Listing
November 2018

Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy.

JAAD Case Rep 2018 May 4;4(4):379-381. Epub 2018 Apr 4.

Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2018.01.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911974PMC
May 2018

Acute visual loss after ipilimumab treatment for metastatic melanoma.

J Immunother Cancer 2016 18;4:66. Epub 2016 Oct 18.

Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA USA ; Present address: Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, C366 MIB 1500 E. Medical Center Drive, SPC5848, Ann Arbor, MI 48109 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0170-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067900PMC
February 2018

Metastatic Merkel cell carcinoma response to nivolumab.

J Immunother Cancer 2016 15;4:79. Epub 2016 Nov 15.

Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, C451 Med Inn, 1500 East Medical Center Drive, Ann Arbor, MI 48109 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0186-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109712PMC
February 2018

Erratum to: Metastatic Merkel cell carcinoma response to nivolumab.

J Immunother Cancer 2017 6;5:27. Epub 2017 Mar 6.

Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, C451 Med Inn, 1500 East Medical Center Drive, Ann Arbor, MI 48109 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0221-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340072PMC
March 2017

Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors.

Biologics 2015 6;9:129-40. Epub 2015 Nov 6.

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S54179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642804PMC
November 2015

Systemic therapy for inoperable and metastatic basal cell cancer.

Authors:
Leslie A Fecher

Curr Treat Options Oncol 2013 Jun;14(2):237-48

Hematology-Oncology, Indiana University Health Simon Cancer Center, 535 Barnhill Drive, RT-473, Indianapolis, IN 46202, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-013-0233-9
Publisher Site
http://dx.doi.org/10.1007/s11864-013-0233-9DOI Listing
June 2013

Ipilimumab and its toxicities: a multidisciplinary approach.

Oncologist 2013 Jun 17;18(6):733-43. Epub 2013 Jun 17.

University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2012-0483DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063401PMC
June 2013

Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

J Am Acad Dermatol 2012 Dec 18;67(6):1265-72. Epub 2012 May 18.

Department of Dermatology, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2012.04.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838029PMC
December 2012

Drug targeting of oncogenic pathways in melanoma.

Hematol Oncol Clin North Am 2009 Jun;23(3):599-618, x

Department of Medicine, Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, 3400 Spruce Street, 16 Penn Tower, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S088985880900040
Publisher Site
http://dx.doi.org/10.1016/j.hoc.2009.03.004DOI Listing
June 2009

Where are we with adjuvant therapy of stage III and IV melanoma in 2009?

J Natl Compr Canc Netw 2009 Mar;7(3):295-304

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2009.0022DOI Listing
March 2009

Effectively targeting BRAF in melanoma: a formidable challenge.

Pigment Cell Melanoma Res 2008 Aug;21(4):410-1

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1755-148X.2008.00485.xDOI Listing
August 2008

The MAPK pathway in melanoma.

Curr Opin Oncol 2008 Mar;20(2):183-9

University of Pennsylvania, Division of Hematology and Oncology, Department of Medicine, The Abramson Cancer Center, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00001622-200803000-000
Publisher Site
http://dx.doi.org/10.1097/CCO.0b013e3282f5271cDOI Listing
March 2008

Toward a molecular classification of melanoma.

J Clin Oncol 2007 Apr;25(12):1606-20

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.06.0442DOI Listing
April 2007